Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. (1st April 2018)

• Record Type: Journal Article
• Authors: Zhang, Nengpan; Li, Chunlin; Zhou, Dayong; Ding, Chen; Jin, Yaqing; Tian, Qingmei; Meng, Xiangzhou; Pu, Kefeng; Zhu, Yimin
• Is Part Of: Acta biomaterialia. Volume 70(2018)
• Page Start: 227
• Page End: 236
• Publication Date: 2018-04-01
• Subjects: cRGD liposomes -- Urokinase -- Platelet targeting -- Thrombosis mouse model -- Thrombolysis; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2018.01.038
• Languages: English
• ISSNs: 1742-7061

Abstract

Graphical abstract: Abstract: Thrombosis, a critical event in blood vessels, not only is associated with myocardial infarction and stroke, but also accounts for considerable morbidity and mortality. Thrombolytic drugs are usually applied to the treatment of acute myocardial infarction, acute cerebral infarction and pulmonary embolism. However, thrombolytic drugs show limited efficacy in clinical practice because of the short half-life in plasma and systemic side effects. In this study, the cyclic RGD (cRGD) functionalized liposomes were prepared to encapsulate urokinase, a cheap and widely used thrombolytic drug in clinic and better thrombolysis efficacy was achieved. The flow cytometry analysis showed that the cRGD liposomes could bind to the activated platelets while not to the resting platelets. In vitro release study revealed that the release percentage reached plateau in about 5 h with 60% urokinase being released from liposomes. Results from the in vitro thrombolysis experiments demonstrated a good thrombolysis potential of the cRGD urokinase liposomes. The in vivo thrombolysis study demonstrated that the cRGD liposomes could significantly reduce the dose of urokinase by 75% while achieving the equivalent thrombolysis effect as the free urokinase in mouse mesenteric thrombosis model. In conclusion, the cRGD liposomes encapsulating urokinase hold great promise in clinic for better thrombolytic efficacy. Statement of Significance: In this paper, the cRGD liposomes were prepared to encapsulate urokinase for targeted thrombolysis therapy. The cRGD liposomes could specifically bind to the activated platelets and could stably and continuously release its loaded urokinase. The mouse mesenteric thrombosis model was established to evaluate the thrombolysis effect of the cRGD urokinase liposomes. The results demonstrated that the cRGD liposomes could improve the thrombolytic efficacy by almost 4-fold over free urokinase. In conclusion, the cRGD liposomes encapsulating urokinase had great potential for the clinical treatment of thrombosis.